Jonathan Schoenfeld Answers: Which Patients Benefit Most from Immunotherapy and Radiation

Video

Jonathan Schoenfeld discusses the patient profile that would benefit best from a combination of radiation and immunotherapy.

Jonathan Schoenfeld, MD, MPhil, MPH, of Dana-Farber Cancer Institute, discusses which patients would benefit most from a combination of immunotherapy and radiation treatment.

Right now, patients with local or locally-advanced disease, or with suppressed immune systems are not thought to be the best candidates for immunotherapy. However, Schoenfeld believes that will change with the advances being made.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
kidney cancer

Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

June 17th 2023
Article

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Ask The Right Questions: Clinical Pearls of AE Management

Ask The Right Questions: Clinical Pearls of AE Management

February 15th 2022
Podcast

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

June 3rd 2023
Article

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

Immunotherapy in the Age of COVID-19

Immunotherapy in the Age of COVID-19

August 15th 2020
Podcast

melanoma

mRNA Vaccine, Plus Pembrolizumab, Minimizes Recurrence Rate in Melanoma

April 22nd 2023
Article

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

biliary tract cancer

Pembrolizumab in Addition to Cisplatin and Gemcitabine Boosts Overall Survival in Advanced Biliary Tract Cancer

April 20th 2023
Article

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

© 2024 MJH Life Sciences

All rights reserved.